REGN
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc historical holders
total: 8
Viking Global Investors Regeneron Pharmaceuticals Inc transactions over time
- Total transactions:
- 8
- New positions:
- 3
- Sold out:
- 3
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2025 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q2
Ole Andreas Halvorsen has been an institutional investor in Regeneron Pharmaceuticals Inc (REGN) since 2014 Q1. According to 2026 Q1 report, Ole Andreas Halvorsen doesn't hold any shares. The fund/company first acquired REGN in 2014 Q1, initially purchasing about 1.05M shares. Ole Andreas Halvorsen later completely sold out the position and reinvested in REGN again in 2025 Q1. Since the initial investment, Viking Global Investors has made 7 more transactions in this position.
When did Ole Andreas Halvorsen exit their REGN position?
Ole Andreas Halvorsen no longer holds Regeneron Pharmaceuticals Inc (REGN). They sold off their entire position in 2025 Q2, closing out an investment that began in 2014 Q1.
When did Ole Andreas Halvorsen first invest in REGN?
Ole Andreas Halvorsen first invested in Regeneron Pharmaceuticals Inc (REGN) in 2014 Q1 at the reported quarter-end price of $300.28 per share, acquiring 1,051,800 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for REGN?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) is approximately $634.23 per share. This represents their average reported price* across all buy transactions.
Has Ole Andreas Halvorsen reinvested in REGN after selling?
Yes, Ole Andreas Halvorsen has shown renewed interest in Regeneron Pharmaceuticals Inc (REGN). After completely selling their position, they reinitiated an investment in 2025 Q1, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $634.23
- Weighted AVG sell price:
- $634.23
REGN transactions history by Viking Global Investors
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.00%
|
0
|
$634.23
|
|
-100% (-97,739)
|
-0.2%
|
|
2025 Q1
|
0.20%
|
97,739
|
$634.23
|
$61,989,006
|
new
|
+0.2%
|
|
2024 Q4
|
0.00%
|
0
|
$1,051.24
|
|
-100% (-49,870)
|
-0.19%
|
|
2024 Q3
|
0.19%
|
49,870
|
$1,051.24
|
$52,425,339
|
new
|
+0.19%
|
|
2014 Q4
|
0.00%
|
$360.52
|
-100% (-1,080,682)
|
|||
|
2014 Q3
|
1.56%
|
$360.52
|
-63.53% (-1,882,774)
|
|||
|
2014 Q2
|
3.65%
|
$282.47
|
+181.75% (+1,911,656)
|
|||
|
2014 Q1
|
1.32%
|
$300.28
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.